Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Knowles signs deal to manufacture Elucent Medical smart surgical guidance device

Knowles signs deal to manufacture Elucent Medical smart surgical guidance device

ReutersReuters2026/08/12 12:11
  • Knowles signed an agreement to manufacture Elucent Medical’s smart surgical guidance device for the EnVisio In-Body Spatial Intelligence System.
  • Production will run at an ISO 13485-certified, FDA-registered facility in Penang, Malaysia.
  • The deal centers on micro molding, design-for-manufacturability work, and vertically integrated assembly to support scale-up and faster commercialization.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Knowles Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: DA24425) on August 12, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Novartis (NVS.US) cardiovascular therapy trial "misfire" drags down Amgen (AMGN.US): stock price plunges to a ten-year low, BMO swiftly downgrades rating

Amgen's stock posted its biggest single-day decline since 2016 on Tuesday, after Novartis announced that a heart disease therapy jointly developed with Ionis Pharmaceuticals suffered a setback in late-stage clinical trials. Meanwhile, BMO downgraded the pharmaceutical giant's rating from "Outperform" to "Market Perform," citing the failure of its candidate drug pelacarsen to meet expectations in its phase III clinical trial.

智通财经2026/09/09 08:11
Novartis (NVS.US) cardiovascular therapy trial "misfire" drags down Amgen (AMGN.US): stock price plunges to a ten-year low, BMO swiftly downgrades rating

NASA contractor Rothe Development rushes to Nasdaq, plans to raise $50 millions

Rothe Development, a contractor that provides engineering and mission operations services to NASA and other federal agencies, filed on Tuesday with the SEC to raise up to $50 million through an initial public offering (IPO).

智通财经2026/09/09 08:11
NASA contractor Rothe Development rushes to Nasdaq, plans to raise $50 millions